Frozen-state storage stability of a monoclonal antibody: Aggregation is impacted by freezing rate and solute distribution

Journal of Pharmaceutical Sciences

Volumn 102, Issue 4, 2013, Pages 1194-1208

  Miller, Maria A ^a   Rodrigues, Miguel A ^a,c   Glass, Matthew A ^a   Singh, Satish K ^b   Johnston, Keith P ^a   Maynard, Jennifer A ^a  

^a The University of Texas at Austin   (United States)

^b PFIZER INC   (United States)

^c INSTITUTO SUPERIOR TÉCNICO   (Portugal)

Author keywords

Biopharmaceuticals characterization; Excipients; Formulation; Protein aggregation; Protein formulation; Stability

Indexed keywords

ICE; IMMUNOGLOBULIN G2; TREHALOSE;

ARTICLE; DIFFUSION; DRUG FORMULATION; DRUG SOLUBILITY; DRUG STABILITY; DRUG STORAGE; FREEZING; PROTEIN CONFORMATION;

EID: 84874723211     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.23473     Document Type: Article

References (52)

1. Nelson AL, Dhimolea E, Reichert JM. 2010. Development trends for human monoclonal antibody therapeutics. Nat Rev Drug Discov 9:767-774.
2. Sheridan C. 2010. Fresh from the biologic pipeline-2009. Nat Biotechnol 28(4):307-310.
3. Kelley B. 2009. Industrialization of mAb production technology: The bioprocessing industry at a crossroads. MAbs 1(5):443-452.
4. Singh S, Kolhe P, Nema S, Wang W. 2009. Large-scale freezing of biologics-A practitioner's review. Part I fundamental aspects. BioProcess Int 7(9):32-44.
5. Webb SD, Webb JN, Hughes TG, Sesin DF, Kincaid AC. 2002. Freezing biopharmaceuticals using common techniques-and the magnitude of bulk-scale freeze-concentration. BioPharm 15(5):22-34.
6. Strambini G, Gabellieri E. 1996. Proteins in frozen solutions: Evidence of ice-induced partial unfolding. Biophys J 70:971-976.
7. Kueltzo LA, Wang W, Randolph TW, Carpenter JF. 2007. Effects of solution conditions, processing parameters and container materials on aggregation of a monoclonal antibody during freeze-thawing. J Pharm Sci 97(5):1801-1812.
8. Carpenter JF, Izutsu K-I, Randolph TW. 2004. Freezing and drying induced perturbations of protein structure and mechanisms of protein protection by stabilizing additives. In Freeze drying/lyophilization of pharmaceutical and biological products; Rey L, May JC, Eds. New York: Marcel Dekker, Inc., pp 147-186.
9. Avastin: EPAR Scientific Discussion. 2006. Accessed 02/01/2013, at: http://www.emaeuropaeu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000582/WC500029262.pdf, ed.
10. Shamlou PA, Breen LH, Bell WV, Pollo M, Thomas BA. 2007. A new scaleable freeze-thaw technology for bulk protein solutions. Biotechnol Appl Biochem 46:13-26.
11. Pikal MJ, Dellerman KM, Roy ML, Riggin RM. 1991. The effects of formulation variables on the stability of freeze-dried human growth hormone. Pharm Res 8(4):427-436.
12. Sarciaux J-M, Mansour S, Hageman MJ, Nail SL. 1999. Effects of buffer composition and processing conditions on aggregation of bovine IgG during freeze-drying. J Pharm Sci 88(12):1354-1361.
13. Pikal-Cleland KA, Rodriguez-Hornedo N, Amidon GL, Carpenter JF. 2000. Protein denaturation during freezing and thawing in phosphate buffer systems: Monomeric and tetrameric beta-galactosidase. Arch Biochem Biophys 384(2):398-406.
14. Bhatnagar BS, Bogner RH, Pikal MJ. 2007. Protein stability during freezing: Separation of stresses and mechanisms of protein stabilization. Pharm Dev Technol 12(5):505-523.
15. Butler MF. 2002. Freeze concentration of solutes at the ice/solution interface studied by optical interferometry. Cryst Growth Des 2(6):541-548.
16. Korber C. 1988. Phenomena at the advancing ice-liquid interface: Solutes, particles and biological cells. Q Rev Biophys 21(2):229-298.
17. Chen YH, Cao E, Cui ZF. 2001. An experimental study of freeze concentration in biological media. Food Bioproducts Process 79(1):35-40.
18. Ayel V, Lottin O, Faucheux M, Sallier D, Peerhossainni H. 2006. Crystallization of undercooled aqueous solutions: Experimental study of free dendritic growth in cylindrical geometry. Int J Heat Mass Transf 49:1876.
19. Rodrigues MA, Miller MA, Glass MA, Singh SK, Johnston KP. 2011. Effect of freezing rate and dendritic ice formation on concentration profiles of proteins frozen in cylindrical vessels. J Pharm Sci 100(4):1316-1329.
20. Wilkins J, Sesin D, Wisniewski R. 2001. Large-scale cryopreservation of biotherapeutic products. Innov Pharm Technol 1(8):174-180.
21. Dong J, Hubel A, Bischof JC, Aksan A. 2009. Freezing-induced phase separation and spatial microheterogeneity in protein solutions. J Phys Chem B 113(30):10081-10087.
22. Miyawaki O, Liu L, Nakamura K. 1998. Effective partition constant of solute between ice and liquid phases in progressive freeze-concentration. J Food Sci 63:756-758.
23. Wisniewski R, Wu V. 1996. Large-scale freezing and thawing of biopharmaceutical products. In Biotechnology and Biopharmaceutical Manufacturing, Processing Preservation, Avis, EA and Wu V, Eds. CRC Press (Boca Raton, Florida), pp 7-59.
24. Butler MF. 2000. Instability formation and directional dendritic growth of ice studied by optical interferometry. Cryst Growth Des 1(3):213.
25. Singh SK, Kolhe P, Mehta AP, Chico SC, Lary AL, Huang M. 2011. Frozen state storage instability of a monoclonal antibody: Aggregation as a consequence of trehalose crystallization and protein unfolding. Pharm Res 28(4):873-885.
26. Singh S, Kolhe P, Nema S, Wang W. 2009. Large-scale freezing of biologics-A practitioner's review. Part II: Practical advice. BioProcess Int 7(10):34-42.
27. Singh S. 2007. Storage consideration as part of the formulation development program for biologics. Am Pharm Rev 10(3):26-33.
28. Singh S, Kolhe P, Wang W, Nema S. 2009. Large-scale freezing of biologics-A practitioner's view. Part II: Practical advice. BioProcess Int 7(10):34-42.
29. Kolhe P, Amend E, Singh SK. 2010. Impact of freezing on pH of buffered solutions and consequences for monoclonal antibody aggregation. Biotechnol Prog 26(3):727-733.
30. Roos Y, Karel M. 1991. Applying state diagrams to food processing and development. Food Technol 45(12):66, 68-71, 107.
31. Garidel P, Hegyi M, Bassarab S, Weichel M. 2008. A rapid, sensitive and economical assessment of monoclonal antibody conformational stability by intrinsic tryptophan fluorescence spectroscopy. Biotechnol J 3:1201-1211.
32. Walton TA, Sousa MC. 2004. Crystal structure of Skp, a prefoldin-like chaperone that protects soluble and membrane proteins from aggregation. Mol Cell 15(3):367-374.
33. Barnard JG, Singh S, Randolph TW, Carpenter JF. 2011. Subvisible particle counting provides a sensitive method of detecting and quantifying aggregation of monoclonal antibody caused by freeze-thawing: Insights into the roles of particles in the protein aggregation pathway. J Pharm Sci 100(2):492-503.
34. Gu X, Suzuki T, Miyawaki O. 2005. Limiting partition coefficient in progressive freeze-concentration. J Food Sci 70(9):546-551.
35. Carpenter JF, Chang BS, Randolph TW. 2004. Physical damage to proteins during freezing, drying, and rehydration. In Lyophilization of biopharmaceuticals; Costantino HR, Pikal MJ, Eds. AAPS Press (Arlington, Virginia), pp 423-442.
36. Webb SD, Cleland JL, Carpenter JF, Randolph TW. 2003. Effects of annealing lyophilized and spray-lyophilized formulations of recombinant human interferon-γ. J Pharm Sci 92(4):715-729.
37. Maa Y-F, Prestrelski SJ. 2000. Biopharmaceutical powders: Particle formation and formulation considerations. Curr Pharm Biotechnol 1:283-302.
38. Pikal-Cleland KA, Cleland JL, Anchordoquy TJ, Carpenter JF. 2002. Effect of glycine on pH changes and protein stability during freeze-thawing in phosphate buffer systems. J Pharm Sci 91(9):1969-1979.
39. Timasheff SN. 1992. Stabilization of protein structure by solvent additives. In Stability of protein pharmaceuticals: Part B; Ahern TJ, Manning MC, Eds. Springer (New York, New York). pp 265-285.
40. Chang BS, Kendrick BS, Carpenter JF. 1996. Surface-induced denaturation of proteins during freezing and its inhibition by surfactants. J Pharm Sci 85(12):1325-1330.
41. Sundaramurthi P, Suryanarayanan R. 2010. Trehalose crystallization during freeze-drying: Implications on lyoprotection. J Phys Chem Lett 1:510-514.
42. Piedmonte DM, Summers C, McAuley A, Karamujic L, Ratnaswamy G. 2007. Sorbitol crystallization can lead to protein aggregation in frozen protein formulations. Pharm Res 24(1):136-146.
43. Zhou R, Schlam RF, Yin S, Gandhi RB, Adams ML. 2010. Scale considerations for selection of saccharide excipients for liquid formulations. J Pharm Sci 100(4):1605-1606.
44. Strambini GB, Gabellieri E. 1996. Proteins in frozen solutions: Evidence of ice-induced partial unfolding. Biophys J 70(2):971-976.
45. Schwegman JJ, Carpenter JF, Nail SL. 2009. Evidence of partial unfolding of proteins at the ice/freeze-concentrate interface by infrared microscopy. J Pharm Sci 98(9):3239-3246.
46. Strambini GB, Gonnelli M. 2007. Protein stability in ice. Biophys J 92:2131-2138.
47. Jiang S, Nail SL. 1998. Effect of process conditions on recovery of protein activity after freezing and freeze-drying. Eur J Pharm Biopharm 45(3):249-257.
48. Webb SD, Cleland JL, Carpenter JF, Randolph TW. 2002. A new mechanism for decreasing aggregation of recombinant human interferon-gamma by a surfactant: Slowed dissolution of lyophilized formulations in a solution containing 0.03% polysorbate 20. J Pharm Sci 91(2):543-558.
49. Engstrom JD, Simpson DT, Cloonan C, Lai ES, Williams III RO, Kitto GB, Johnston KP. 2007. Stable high surface area lactate dehydrogenase particles produced by spray freezing into liquid nitrogen. Eur J Pharm Biopharm 65:163-174.
50. Engstrom JD, Simpson DT, Lai ES, Williams III RO, Johnston KP. 2007. Morphology of protein particles produced by spray freezing of concentrated solutions. Eur J Pharm Biopharm 65:149-162.
51. Engstrom JD, Lai ES, Ludher BS, Chen B, Milner TE, Williams III RO, Kitto GB, Johnston KP. 2008. Formation of stable submicron protein particles by thin film freezing. Pharm Res 25(6):1334-1346.
52. Miller MA, Khan TA, Kaczorowski KJ, Wilson BK, Dinin AK, Rodrigues MA, Johnston KP, Maynard JA. 2012. Antibody nanoparticle dispersions formed with mixtures of crowding molecules retain activity and in vivo bioavailability. J Pharm Sci 101:3763-3778.